Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Unichem

- PMLiVE

Building a bright future

Mylan takes a bold approach as it doubles its pipeline through R&D and acquisitions

- PMLiVE

Teva faces early rival to longer-acting Copaxone in US

US regulator approves Mylan’s MS drug

Teva’s Mark Salyer joins Amarin

Takes up newly-created chief commercial officer role

- PMLiVE

Teva offloads women’s health unit in quickfire deals

The Israeli pharma group is also set to sell its oncology and pain business

- PMLiVE

Teva poaches Lundbeck’s Schultz as new CEO

Shares in Lundbeck fall as two senior posts become vacant

- PMLiVE

FDA clears Teva’s tardive dyskinesia drug Austedo

The twice-daily drug will compete with Neurocrine Bioscience’s Ingrezza

- PMLiVE

Teva to cut 7000 jobs, close 15 manufacturing sites

Missed second-quarter sales expectations prompt the cutbacks

- PMLiVE

NICE backs Teva’s Cinqaero for severe asthma

Ruling will allow it to compete with GSK's rival IL-5 inhibitor Nucala

- PMLiVE

FDA panel backs Avastin and Herceptin biosimilars

A decision from the US regulator is expected in September

AstraZeneca AZ

AZ on the slide again as CEO departure rumours bubble away

Soriot’s alleged departure makes investors nervous ahead of looming MYSTIC trial results

EU flag

EU starts investigation of Aspen’s cancer drug pricing

Amid reports of price increases of several hundred per cent

- PMLiVE

Teva drops laquinimod for most common form of MS after failed trial

CONCERTO study showed no disability progression improvements over placebo

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links